Clinical trials: Idarubicin
Leukemia, Promyelocytic, Acute
Acute Promyelocytic Leukemia 2006 (APL)
To assess the role of Arsenic trioxide and/or ATRA during consolidation course in APL. It is hoped that the investigational arms will further increase the event-free survival at 2 years, with reduced toxicity and without…
- Trial name
- NCT00378365
- Testing
- Arsenic trioxide, ATRA
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoid Leukemia (ALL)
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
This single-arm, prospective, multicenter, phase II study will enroll newly diagnosed Philadelphia chromosome-negative (Ph-) acute B-cell lymphoblastic leukemia (B-ALL) patients aged 18-60 years.
- Trial name
- NCT06930105
- Testing
- Blinatumomab plus Reduced-dose Chemotherapy
- Volunteers
- 45 people
- Sponsor
- Xianmin Song, MD
Leukemia
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine…
- Trial name
- NCT01018069
- Testing
- AEG35156
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 60 people
- Sponsor
- Aegera Therapeutics
Hepatocellular Carcinoma, Liver Cancer
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma
Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma.
- Trial name
- IDADOX (NCT06114082)
- Testing
- IDA-TACE, DOX-TACE
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Seoul National University Hospital
Acute Myeloid Leukemia, Leukemia, Acute Myeloid
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus…
- Conditions
- Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute
- Trial name
- SIERRA (NCT02665065)
- Testing
- Iomab-B, Conventional Care, HCT
- Where
- 24 sites in United States, Canada
- Volunteers
- 153 people
- Sponsor
- Actinium Pharmaceuticals
Acute Myeloid Leukemia
Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML)
A phase II clinical trial evaluating the efficacy and tolerability of induction and consolidation chemotherapy comprising Fludarabine, cytarabine and attenuated-dose Idarubicin (modified-FLAI) in the elderly patients with acute…
- Trial name
- m-FLAI (NCT01247493)
- Testing
- induction chemotherapy (fludarabine, cytarabine, idarubicin)
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
In this study, patients with hepatocellular carcinoma were used as the research object to explore the effectiveness and safety of idarubicin hepatic artery perfusion combined with lipiodol embolization, and to preliminarily…
- Trial name
- NCT05053386
- Testing
- Idarubicin Hydrochloride for Injection, Epirubicin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhejiang Cancer Hospital
Acute Myeloid Leukemia
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
The purpose of this study is to characterize the regimen limiting toxicities (RLT) and recommended Phase 2 dose (RP2D) of indoximod in patients with newly diagnosed AML receiving remission induction chemotherapy with cytarabine…
- Trial name
- NCT02835729
- Testing
- Idarubicin, Cytarabine, Indoximod Freebase
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- NewLink Genetics Corporation
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
This randomized phase I trial is studying the side effects and best dose of vorinostat when given together with idarubicin in treating patients with relapsed or refractory leukemia or myelodysplastic syndromes.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00331513
- Testing
- vorinostat, idarubicin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Acute Myeloid (AML)
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared…
- Trial name
- NCT05586074
- Testing
- Clifutinib, LoDAC, Azacitidine
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Acute Myeloid Leukemia (AML)
Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia
This study aims to investigate the safety and efficacy of drug "X" in combination with intensive chemotherapy in subjects with newly diagnosed AML (excluding APL and CBF-AML).
- Trial name
- NCT06652685
- Testing
- D5-PBCR(-) IA arm, D5-PBCR(+) IA+Venetoclax arm
- Where
- China
- Volunteers
- 218 people
- Sponsor
- Ruijin Hospital
Leukemia, Acute, Leukemia, T Cell
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this…
- Conditions
- Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic
- Trial name
- NCT03553238
- Testing
- Chidamide, Dexamethasone, vincristine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Leukemia, Myelodysplastic Syndromes
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00002800
- Testing
- filgrastim, lintuzumab, cytarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Core Binding Factor Acute Myeloid Leukemia
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
Core-binding factor acute myeloid leukemia accounts for 10-15% of AML and is categorized as favorable-risk AML. However, the 5-year CIR was up to 40% in this group of patients.
- Trial name
- NCT05404516
- Testing
- Sorafenib, Idarubicin, Cytarabine
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Newly Diagnosed AML With FLT3 Activating Mutations
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3…
- Trial name
- NCT02283177
- Testing
- crenolanib, cytarabine, daunorubicin
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Arog Pharmaceuticals, Inc.
ALL, Adult, Philadelphia-Negative ALL
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
In this study, newly diagnosed non-elderly patients with Philadelphia chromosomal negative (PH-) B-ALL were enrolled and 1:1 randomised into Reduced-intensity chemotherapy followed by Blinatumomab cohort or hyperCVAD cohort as…
- Trial name
- BEAT-ALL-2024 (NCT06250959)
- Testing
- Blinatumomab Injection [Blincyto], Doxorubicin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Chen Suning
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003603
- Testing
- cyclophosphamide, dexamethasone, idarubicin
- Where
- United Kingdom
- Volunteers
- 660 people
- Sponsor
- Riverside Haematology Group
Lymphoma, B-Cell
Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma
The main objective of the trial is to assess the therapeutic activity of idarubicin as salvage treatment in patients with recurrent or progressive lymphoma in the central nervous system.
- Trial name
- NCT00210366
- Testing
- Idarubicin
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University
Acute Myeloid Leukemia
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
The purpose of this study is to test the safety and determine the best dose of venetoclax and cytarabine when given with or without idarubicin in treating pediatric patients with acute myeloid leukemia (AML) that did not respond…
- Trial name
- NCT03194932
- Testing
- Venetoclax, Cytarabine, Idarubicin
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- St. Jude Children's Research Hospital